NOVALIQ GmbH
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.novaliq.de
Clinical Trials
12
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
A Clinical Trial to Evaluate the Corneal Endothelial Health of DED Subjects Treated With Cyclosporine
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Saline solution, 0.6%
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 204
- Registration Number
- NCT06329661
- Locations
- 🇺🇸
CYS-007 Investigational Site, Memphis, Tennessee, United States
ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
- Conditions
- Dry Eye Disease
- Interventions
- Drug: CyclASol topical ocular, eye dropsDrug: Vehicle topical ocular, eye drops
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 834
- Registration Number
- NCT04523129
- Locations
- 🇺🇸
CYS-004 Investigational Site, Seattle, Washington, United States
🇺🇸CYS-004 Investigational site, Ogden, Utah, United States
🇺🇸CYS-004 Investigation Site, Kansas City, Missouri, United States
CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Drug: CyclASol Ophthalmic Solution
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 202
- Registration Number
- NCT04523142
- Locations
- 🇺🇸
CYS-005 Investigational Site, Lynchburg, Virginia, United States
🇺🇸CYS-005 Investigtional Site, Raynham, Massachusetts, United States
Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye
- Conditions
- Evaporative Dry Eye Disease
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT04521465
- Locations
- 🇩🇪
NTO-001 Investigational Site, Nürnberg, Germany
Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Novaliq GmbH
- Target Recruit Count
- 336
- Registration Number
- NCT03333057
- Locations
- 🇺🇸
Investigational site, Jacksonville, Florida, United States
🇺🇸Investigational Site, Nashville, Tennessee, United States
- Prev
- 1
- 2
- 3
- Next
News
Eyenovia and Betaliq Plan Reverse Merger to Create Innovative Ophthalmic Technology Company
Eyenovia has entered into a non-binding letter of intent with Betaliq to create a new publicly-listed eye care company valued at approximately $92 million, with Betaliq shareholders owning 83.7% of the combined entity.
Perfluorohexyloctane Shows Promise for Dry Eye Disease in Pooled Phase 3 Analysis
Pooled data from two Phase 3 trials (GOBI and MOJAVE) demonstrate that perfluorohexyloctane ophthalmic solution significantly improves signs and symptoms of dry eye disease (DED).